Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitry V Shcheblyakov

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Emerging Microbes & Infections|August 29, 2022
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primatesAmir I Tukhvatulin, Ilya V Gordeychuk, Inna V Dolzhikova, et al.
Lancet (London, England)|September 8, 2020
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from RussiaDenis Y Logunov, Inna V Dolzhikova, Olga V Zubkova, et al.
Lancet (London, England)|February 5, 2021
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaDenis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov, et al.
Frontiers in Immunology|December 5, 2022
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virusVladimir A Gushchin, Darya A Ogarkova, Inna V Dolzhikova, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Emerging Microbes & Infections|August 29, 2022
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primatesAmir I Tukhvatulin, Ilya V Gordeychuk, Inna V Dolzhikova, et al.
Lancet (London, England)|September 8, 2020
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from RussiaDenis Y Logunov, Inna V Dolzhikova, Olga V Zubkova, et al.
Lancet (London, England)|February 5, 2021
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaDenis Y Logunov, Inna V Dolzhikova, Dmitry V Shcheblyakov, et al.
Frontiers in Immunology|December 5, 2022
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virusVladimir A Gushchin, Darya A Ogarkova, Inna V Dolzhikova, et al.
Pageof 4